Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome

Neurological Research

Volumn 33, Issue 4, 2011, Pages 415-420

  Sladkova, Vladimira ^a   Mareš, Jan ^a   Lubenova, Blanka ^a   Zapletalova, Jana ^a   Stejskal, David ^a   Hlustik, Petr ^a   Kanovsky, Petr ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

CIS; CSF; Degenerative markers; Inflammatory markers; Multiple sclerosis; RRMS

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA 2 MICROGLOBULIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYSTATIN C; HAPTOGLOBIN; IMMUNOGLOBULIN G; NEURON SPECIFIC ENOLASE; OLIGOCLONAL BAND; OROSOMUCOID; PREALBUMIN; TAU PROTEIN; TRANSFERRIN;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID PROTEINS; DEMYELINATING DISEASES; FEMALE; HUMANS; IMMUNOGLOBULINS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE DEGENERATION; NERVE TISSUE PROTEINS; PREDICTIVE VALUE OF TESTS; YOUNG ADULT;

EID: 79955969170     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164110X12816242542535     Document Type: Article

References (30)

1. Kieseier BC. Assessing long-term effects of disease modifying drugs. J Neurol 2006;253:VI/23-VI/30.
2. Franciotta D. Biological markers in multiple sclerosis. Int MS J 2004;11:86-94.
3. Gonsette RS. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 2008;274:48-53.
4. Confavreux C, Vukusic S. Multiple sclerosis: a degenerative disease? Bull Acad Natl Med 2008;192:483-91.
5. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006;180:17-28.
6. Petereit HF, Reske D. Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients-follow-up and clinical implications. Cerebrospinal fluid Res 2005;27:2-3.
7. Padilla-Docal B, Dorta-Contreras AJ, Fundora-Hernández H, Noris-García E, Bu-Coifiu-Fanego R, González-Hernández M, et al. C3c intrathecal synthesis evaluation in patients with multiple sclerosis. Arq Neuropsiquiatr 2007;65:800-2.
8. Sellebjerg F, Jaliashvili I, Christiansen M, Garred P. Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci 1998;157:168-74.
9. Zeman D, Adam P, Kalistova H, Sobek O, Kelbich P, Andel J, et al. Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients. Acta Neurol Scand 2000;101:89-94.
10. Adam P, Sobek O, Taborsky L, Hildebrand T, Tutterova O, Zacek P. CSF and serum orosomucoid (alpha-1-glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients. Clin Chim Acta 2003;334:107-10.
11. Adam P, Taborsky L, Sobek O. Proteinocytology of cerebrospinal fluid. Prague: Medica New Publisher; 2002.
12. Niezgoda A, Losy J, Mehta PD. Effect of cladribine treatment on beta-2-microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis. Folia Morphol 2001;60:225-8.
13. Bagdato F, Zivadinov R, Cecchinelli D, Tancredi A, Grop A, Pierandini A, et al. Beta-2-microglobulin serum level is not marker of disease activity in multiple sclerosis. Eur J Neurol 2004;11:455-60.
14. Rumbach L, Grucker M, Kiesmann M, Warter JM, Collard M. Biochemical analysis of the cerebrospinal fluid in multiple sclerosis: study of various formulas. Pathol Biol 1988;36:1217-20.
15. Mares J, Stejskal D, Vavrouskova J, Urbanek K, Herzig R, Hlustik P. Use of cystatin C determination in clinical diagnostics. Biomed Pap 2003;147:177-80.
16. Bollengier F. Cystatin C, alias post-gamma-globulin: a marker for multiple sclerosis? J Clin Chem Clin Biochem 1987;25:589-93.
17. Nakashima I, Fujinoki M, Fujihara K, Kawamura T, Nakamura M, Itoyama Y. Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. Ann Neurol 2007;62:197-200.
18. De Serres FJ. Alpha-1-antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed. Environ Health Perspect 2003;111:1851-4.
19. Lolin YI, Ward AM. Alpha-1-antitrypsin phenotypes and associated disease patterns in neurological patients. Acta Neurol Scand 1995;91:394-8.
20. Jiménez-Jiménez FJ, Zunfo JM, Hernanz A, Medina-Acebrón S, De Bustos F, Barcenilla B, et al. Tau protein concentration in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 2002;106:351-4.
21. Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006;12:143-8.
22. Martínez-Yélamos A, Saiz A, Bas J, Hernandez JJ, Graus F, Arbizu T. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett 2004;363:14-7.
23. Guimaräes J. Tau protein seems not to be a useful clinical marker of axonal damage in multiple sclerosis. Mult Scler 2006;12:354-6.
24. Gehrmann J, Banati RB, Cuzner ML, Kreutzberg GW, Newcombe J. Amyloid precursor protein (APP) expression in multiple sclerosis lesions. Glia 1995;15:141-51.
25. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Brück W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000;123:1174-83.
26. Hein Neé Maier K, Kohler A, Diem R, Sattler MB. Demmer I, Lange P, et al. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neurosci Lett 2008;436:72-6.
27. Koch M, Mostert J, Heersema D, Teelken A, De Keyser J. Plasma S100beta and NSE levels and progression in multiple sclerosis. J Neurol Sci 2007;252:154-8.
28. Osman I, Gaillard O, Meillet D, Bordas-Fonfrède M, Gervais A, Schuller E, et al. A sensitive time-resolved immunofluorometric assay for the measurement of apolipoprotein B in cerebrospinal fluid. Application to multiple sclerosis and other neurological diseases. Eur J Clin Chem Clin Biochem 1995;33:53-8.
29. Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev 2002;1:111-7.
30. Gelman BB, Rifai N, Christenson RH, Silverman LM. Cerebrospinal fluid and plasma apolipoproteins in patients with multiple sclerosis. Ann Clin Lab Sci 1988;18:46-52.